Long-term safety of twice-daily aclidinium bromide in COPD patients: A one-year, double-blind study

被引：0
|
作者：
Gelb, Arthur [1 ]
Tashkin, Donald [2 ]
Make, Barry [3 ]
Zhong, Xiaoyun [4 ]
Gil, Esther Garcia [5 ]
Caracta, Cynthia [6 ]
机构：
[1] Southern Calif Clin Trials, Lakewood, CO USA
[2] UCLA, Div Pulm & Crit Care Med, David Geffen Sch Med, Los Angeles, CA USA
[3] Natl Jewish Hlth, Dept Med, Denver, CO USA
[4] Forest Res Inst, Biostat, Jersey City, NJ USA
[5] Almirall SA, R&D Ctr, Barcelona, Spain
[6] Forest Res Inst, Clin Dev, Jersey City, NJ USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2012年 / 40卷
关键词：
COPD; -; management; Bronchodilators; Exacerbation;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
3536
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Fremanezumab Long-Term Efficacy and Safety: Interim Results of a One-Year Study
    Goadsby, P.
    Yeung, P. P.
    Blankenbiller, T.
    Grozinski-Wolff, M.
    Yang, R.
    Ma, Y.
    Ning, X.
    Aycardi, E.
    HEADACHE, 2018, 58 : 166 - 166
  • [32] A double-blind study evaluating the long-term safety of varenicline for smoking cessation
    Williams, Kathryn E.
    Reeves, Karen R.
    Billing, Clare B., Jr.
    Pennington, Ann M.
    Gong, Jason
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (04) : 793 - 801
  • [33] Long-term Safety of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol Fumarate in Patients With Stable Moderate to Severe COPD
    Make, Barry
    Donohue, James
    Zhong, Xiaoyun
    Leselbaum, Anne
    Caracta, Cynthia
    CHEST, 2014, 145 (03)
  • [34] Safety and tolerability of twice-daily balsalazide tablets: Results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study
    Pruitt, Ronald E.
    Rosen, Alan A.
    Wruble, Lawrence
    Sedghi, Shahriar
    Shepard, Roland D.
    Mareya, Shadreck M.
    Huang, Shirley
    Shaw, Audrey L.
    Forbes, William F.
    GASTROENTEROLOGY, 2008, 134 (04) : A494 - A494
  • [35] SOTALOL IN MILD TO SEVERE HYPERTENSION - TWICE-DAILY AND ONCE-DAILY ADMINISTRATION - LONG-TERM STUDY
    REYNAERT, J
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1979, 26 (06): : 799 - 812
  • [36] Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial
    Ben Abdallah, Saoussen
    Mhalla, Yosra
    Trabelsi, Imen
    Sekma, Adel
    Youssef, Rim
    Ali, Khaoula Bel Haj
    Ben Soltane, Houda
    Yacoubi, Hajer
    Msolli, Mohamed Amine
    Stambouli, Nejla
    Beltaief, Kaouthar
    Grissa, Mohamed Habib
    Khrouf, Meriem
    Mezgar, Zied
    Loussaief, Chawki
    Bouida, Wahid
    Razgallah, Rabie
    Hezbri, Karima
    Belguith, Asma
    Belkacem, Naouel
    Dridi, Zohra
    Boubaker, Hamdi
    Boukef, Riadh
    Nouira, Semir
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (02) : 185 - 191
  • [37] DOUBLE-BLIND COMPARISON OF THE EFFICACY AND TOLERABILITY OF ONCE-DAILY VS TWICE-DAILY DOSAGES OF DICLOFENAC SODIUM TO PATIENTS WITH ARTHROSIS
    BROLIN, L
    ERICSSON, J
    MILOSEVIC, A
    PETTERSSON, G
    SIKEN, L
    VIERING, S
    WARMENIUS, S
    BJORKMAN, R
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1988, 44 (06): : 890 - 895
  • [38] Long-Term Safety Of Fixed-Dose Combination Aclidinium Bromide/formoterol Fumarate In Patients With Moderate To Severe COPD: The Augment COPD Extension Trial
    Rennard, S. I.
    D'Urzo, A. D.
    Donohue, J. F.
    He, T.
    Shrestha, P.
    Leselbaum, A.
    Caracta, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [39] BACLOFEN - DOUBLE-BLIND CROSSOVER AND LONG-TERM STUDY
    FELDMAN, RG
    HAYES, MK
    CONOMY, J
    FOLEY, J
    NEUROLOGY, 1978, 28 (04) : 333 - 333
  • [40] Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study
    Kerwin, Edward
    Siler, Thomas M.
    Korenblat, Phillip
    White, Alexander
    Eckert, Joerg H.
    Henley, Michelle
    Patalano, Francesco
    D'Andrea, Peter
    CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION, 2016, 3 (02): : 549 - 559
12345